Key figures (consolidated)
|
|
- Howard Dalton
- 5 years ago
- Views:
Transcription
1 Nestlé Group 2013
2 Key figures (consolidated) In millions of CHF (except for data per share) 2013 Results Sales Trading operating profit as % of sales 15.2% Profit for the year attributable to shareholders of the parent (Net profit) as % of sales 10.9% Balance sheet and Cash flow statement Equity attributable to shareholders of the parent before proposed appropriation of profit of Nestlé S.A. Net financial debt Ratio of net financial debt to equity (gearing) Operating cash flow Free cash flow (a) Capital expenditure as % of sales % %
3 Data per share Total basic earnings per share Underlying (b) Dividend as proposed by the Board of Directors of Nestlé S.A. Stock exchange prices (high/low) Yield (c) Market capitalisation, end December CHF CHF CHF CHF % / / (a) Operating cash flow less capital expenditure, expenditure on intangible assets, sales of property, plant and equipment, investments (net of divestments) in associates and joint ventures, and other investing cash flows. (b) Profit per share for the year attributable to shareholders of the parent before impairments, restructuring costs, results on disposals and significant one-off items. The tax impact from the adjusted items is also adjusted for. (c) Calculated on the basis of the dividend for the year concerned, which is paid in the following year, and on high/low stock prices.
4 Analysis of sales, trading operating profit and organic growth (OG) By operating segment In millions of CHF Zone Europe Zone Americas Zone Asia, Oceania and Africa Nestlé Waters Nestlé Nutrition Other (a) Unallocated items (b) Total Group Sales Trading operating profit (1809) OG 0.8% 5.3% 5.6% 2.0% 8.2% 5.4% 4.6%
5 By product In millions of CHF Powdered and Liquid Beverages Water Milk products and Ice cream Nutrition and HealthCare Prepared dishes and cooking aids Confectionery PetCare Unallocated items (b) Total Group (a) Mainly Nespresso, Nestlé Professional and Nestlé Health Science. (b) Mainly corporate expenses as well as research and development costs. Sales Trading operating profit (1809) OG 4.6% 1.8% 5.8% 7.6% 0.3% 5.0% 6.8% 4.6%
6 Contact Media Nestlé S.A. Corporate Media Relations Avenue Nestlé 55 CH-1800 Vevey (Switzerland) Tel. +41 (0) Fax +41 (0) Investors Nestlé S.A. Investor Relations Avenue Nestlé 55 CH-1800 Vevey (Switzerland) Tel. +41 (0) Fax +41 (0) Shareholders Share register: registrations, transfers, address changes, dividends, etc. Nestlé S.A. Share Transfer Office Zugerstrasse 8 CH-6330 Cham (Switzerland) Tel. +41 (0) Fax +41 (0) shareregister@nestle.com
7 Company profile Nestlé has sold its products in 196 countries, has 447 factories in 86 countries and employees. Employees by geographic area Europe* Americas Asia, Oceania and Africa Total * employees in Switzerland in % 32.5% 39.5% 100.0% Factories by geographic area Europe Americas Asia, Oceania and Africa Total
8 The Nestlé Story all the way to Nutrition, Health and Wellness 1866 Foundation of Anglo-Swiss Condensed Milk Co Henri Nestlé s Infant cereal developed 1905 Nestlé and Anglo-Swiss Condensed Milk Co. (new name after merger) 1929 Merger with Peter, Cailler, Kohler Chocolats Suisses S.A Launch of Milo 1938 Launch of Nescafé 1947 Nestlé Alimentana S.A. (new name after merger with Maggi) 1948 Launch of Nestea and Nesquik 1969 Vittel (initially equity interest only) 1971 Merger with Ursina-Franck 1973 Stouffer (with Lean Cuisine) 1974 L Oréal (associate)
9 1977 Nestlé S.A. (new name), Alcon (disposed in August 2010) 1981 Galderma (joint venture with L Oréal full acquisition announced for 2014) 1985 Carnation (with Coffee-mate and Friskies) 1986 Creation of Nestlé Nespresso S.A. and Herta 1988 Buitoni-Perugina and Rowntree (with KitKat) 1990 Cereal Partners Worldwide (joint venture with General Mills) 1991 Beverage Partners Worldwide (joint venture with Coca-Cola) 1992 Perrier (with Poland Spring) 1993 Creation of Nestlé Sources Internationales (2002: Nestlé Waters) 1997 Creation of Nutrition Strategic Business Division (2006: Nestlé Nutrition) 1998 Sanpellegrino and Spillers Petfoods, Launch of Nestlé Pure Life 2000 PowerBar (disposal announced for 2014) 2001 Ralston Purina
10 2002 Schöller, Chef America and Dairy Partners Americas (joint venture with Fonterra) Laboratoires innéov (joint venture with L Oréal) 2003 Mövenpick and Dreyer s 2005 Wagner 2006 Creation of FoodServices Strategic Business Division (2009: Nestlé Professional) Lactalis Nestlé Produits Frais (associate) Jenny Craig (disposed in 2013), Uncle Tobys and Delta Ice Cream 2007 Novartis Medical Nutrition, Gerber, Henniez 2008 Ruzanna 2010 Kraft Food s frozen pizza, Waggin Train, Malher, Technocom and Vitaflo 2011 Creation of Nestlé Health Science and Nestlé Institute of Health Sciences Yinlu, Hsu Fu Chi (partnerships) 2012 Wyeth Nutrition 2013 Pamlab
11 Our ambition Nestlé s ambition is to enhance the quality of consumer s lives through nutrition, health and wellness. We offer healthier and tastier choices throughout all stages of a consumer s life and at any time of the day. Based on science and Research and Development, we permanently innovate our portfolio of food and beverages. We have reinforced this strategy by extending the boundaries of nutrition with Nestlé Health Science, enabling us to develop nutritional solutions based on science to help prevent and treat various health conditions. With the recent setting up of Nestlé Skin Health, we are extending the boundaries of health and wellness further, into the field of specialised medical skin treatment. It is our firm belief that for a company to be successful over time, and create value for its shareholders, it must also create value for society. We call this Creating Shared Value. Built on strong foundations of compliance and sustainable business practices, this is our way of doing business and of being the trusted leader in Nutrition, Health and Wellness.
12 Operational pillars Growth drivers The Nestlé Roadmap to Good Food, Good Life Innovation and renovation Nutrition, Health and Wellness Emerging markets and Popularly Positioned Products In recent years the Nestlé 4x4x4 Roadmap has helped us build both a strong alignment within our Company and a deep understanding of what we want to achieve, strategically and financially, and how to go about it. Our commitment is to provide Good Food, Good Life. Whenever, wherever, however Operational efficiency Consumer engagement Compliance Sustainability Nestlé culture, values and principles Creating Shared Value Our objective is to be the leader in Nutrition Health and Wellness, and the industry reference for financial performance, trusted by all stakeholders Out-of-home consumption Premiumisation Unmatched product and brand portfolio People, culture, values and attitude Competitive advantages Unmatched geographic presence Unmatched research and development capability
Welcome to the Full -Year Results Press Conference
Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements
More informationAutumn Press Conference October 2005
Autumn Press Conference 2005 20 October 2005 Key Figures Nestlé Group organic growth 5.8 % Food and Beverage organic growth 5.6% (RIG 3.5% + pricing 2.1%) Reported sales CHF 67.7 billion (+ 4.8%) 2 AUTUMN
More informationWelcome to the Nine-Month Sales Conference
Welcome to the Nine-Month Sales Conference Nine-Month Sales Conference Paul Bulcke Nestlé CEO Nine-Month Sales Conference Wan Ling Martello Chief Financial Officer Disclaimer This presentation contains
More informationWelcome to the New York Press Conference
Welcome to the New York Press Conference Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements involve
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationKey figures by management responsibility and geographic area
Management Report 2003 Nestlé s strategic priorities are focused on delivering shareholder value through the achievement of sustainable, capital efficient and profitable long-term growth Key figures Key
More informationWHAT. Cereals Coffee Water Other drinks Shelf stable Chilled Ice cream Infant foods Performance nutrition
WHO WHAT Cereals Coffee Water Other drinks Shelf stable Chilled Ice cream Infant foods Performance nutrition Health care nutrition Seasonings Frozen foods Refrigerated products Chocolate, confectionery
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationNestlé Dairy s new frontier: healthy ageing
Nestlé Dairy s new frontier: healthy ageing Thierry Philardeau Head of Dairy SBU Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates.
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationCreating Shared Value and meeting our commitments
Creating Shared Value and meeting our commitments Swiss Sustainability Leaders SRI Conference Zug, Janet Voûte Vice President, Global Head of Public Affairs Nestlé Nestlé at a glance Started in 1866 as
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationNutrition, Health & Wellness The Nestlé Perspective. Paul Bulcke Chief Executive
Nutrition, Health & Wellness The Nestlé Perspective Paul Bulcke Chief Executive 10 March 2010 Disclaimer This presentation contains forward looking statements which reflect Management s current views and
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationBoiron Group confirms its forecasts for year 2008 : sales increase and growth in current operating income.
2008 FIRST QUARTER ACTIVITY IFRS - In thousands of Euros 2007 2007 2008 constant France (1) 0,000 66,087 65,728-0.5% -0.5% Europe excluding France 0,000 33,221 41,346 +24.5% +23.2% North America 0,000
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationNestlé in the USA & Frozen Meals Performance. February 23, 2017 Jeff Hamilton President Nestlé Food Division Nestlé USA
Nestlé in the USA & Frozen Meals Performance February 23, 2017 Jeff Hamilton President Nestlé Food Division Nestlé USA Disclaimer This presentation contains forward looking statements which reflect Management
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationNestlé. In Society. Creating Shared Value Progress and Commitments Middle East
Nestlé In Society Creating Shared Value Progress and Commitments 2020 Middle East Nestlé s purpose is about enhancing quality of life and contributing to a healthier future. We have identified three areas
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationDuPont Nutrition & Health Craig Binetti, President
Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this
More informationEfforts start to pay off in the fourth quarter
2014 annual sales (1 st January to 31 December 2014) Efforts start to pay off in the fourth quarter Double-digit growth for Food & Beverage in the US (excluding scope effect) Double-digit growth in emerging
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationThromboGenics Business Update H1 2018
Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion
More informationNestlé UK & Ireland: Contributing to a healthier future 2018
www.nestle.co.uk Nestlé UK & Ireland: Contributing to a healthier future 2018 2.6 billion teaspoons 10,400 7.4% sugar reduction already achieved Nestlé confectionery well on the way to 10% sugar reduction
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationGlobal Market for Infant Formula and Dairy Ingredients
Global Market for Infant Formula and Dairy Ingredients 2015-2020 Published in September 2016 1 Report outline 1. Introduction 2. Infant formula market 3. Infant formula industry 4. Dairy ingredients used
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationExpanding the boundaries of nutrition Luis Cantarell
Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationFRUIT STARCH SUGAR. AGRANA Beteiligungs-AG. The natural upgrade. Corporate presentation
FRUIT STARCH SUGAR The natural upgrade AGRANA Beteiligungs-AG Corporate presentation 2018 1 ABOUT US AGRANA FACTS We refine agricultural raw materials, turning them into a range of different industrial
More informationNestlé New Zealand. Healthy Kids Industry Pledge. Our nutrition commitments
Nestlé New Zealand Healthy Kids Industry Pledge Our nutrition commitments 2017 2020 Introducing our 2020 nutrition Supporting individuals and their families with tastier and healthier food choices Launch
More informationCREATING SHARED VALUE Nestlé and Nestlé Purina in the U.S.
CREATING SHARED VALUE Nestlé and Nestlé Purina in the U.S. Nestlé and Nestlé Purina -- We re Focused on Creating Shared Value in Every Aspect of our Business: Nutrition, Quality & Food Safety Environment
More informationVision. Mission. Hopelink s Values. Introduction. A community free of poverty
Vision A community free of poverty Mission Hopelink s mission is to promote self-sufficiency for all members of our community; we help people make lasting change. Hopelink s Values Growth and Human Potential
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationNestlé global commitment to sodium reduction
Nestlé global commitment to sodium reduction Multilateral Consortium Meeting for Dietary Salt Reduction, PAHO, 28-29 th August 2012 Henri-Pierre Lenoble Nestlé Nestlé is committed to engage on sodium reduction
More informationEnvironmental, Health and Safety
Environmental, Health and Safety Codes of Practice The Environmental, Health and Safety (EHS) Codes of Practice set forth Zimmer EHS requirements for our business functions and facilities worldwide. In
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationJTI Switzerland. JTI Schweiz 3
JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationSirma Group Holding JSC. Consolidated financial statements for the year ending December 31, 2016
Sirma Group Holding JSC Consolidated financial statements for the year ending December 31, 216 Changes in share prices for the period ending 31.12.216 Last trading price on 3.12 1.189 BGN Change in share
More informationThe New Danone : A unique food company. Autumn Conference 2008 CA Cheuvreux
The New Danone : A unique food company Autumn Conference 2008 CA Cheuvreux September 26th, 2008 Disclaimer This document contains certain forward-looking statements concerning Groupe DANONE. Although Groupe
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationADM to Acquire WILD Flavors
ADM to Acquire WILD Flavors Creating a Leading Global Flavors and Specialty-Ingredients Business July 7, 2014 ARCHER DANIELS MIDLAND COMPANY 1 Safe Harbor Statement Some of our statements constitute forward-looking
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationNestlé Health Science Overview
Nestlé Health Science Overview David Yates North America Regional Business Head Nestlé Investor Seminar Boston, June 3-4, 2014 Disclaimer This presentation contains forward looking statements which reflect
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationNestlé Investor Seminar 2007
Nestlé Investor Seminar 2007 Nestlé Research The Engine for Nutrition, Health and Wellness Prof. Dr-Ing. Werner Bauer Chief Technology Officer 1 Nestlé Investor Seminar - Vevey June 7-8, 2007 Name of chairman
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationLars Dahlgren. President and CEO
Lars Dahlgren President and CEO 1 Summing up 2013 Sales in line with last year but decreasing profits Sales +1% Operating profit -5% Earnings per share 13.63 SEK (14.33) Financially challenging year but
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More informationVery good Q3 contribution from Vegetable Juices Inc.
2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release
More informationBoehringer Ingelheim and investment in R&D. Volker Barkmann
Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation
More informationConsumer Care A Strong Foundation in Consumer Health
Consumer Care A Strong Foundation in Consumer Health Spring Investors Conference 2004 Leverkusen, March 19, 2004 Gary S. Balkema President Consumer Care Division Safe Harbor This presentation contains
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationIndustry experience in consortium i.e. from BEE party or non-bee partners
A. ENTREPRENEURSHIP FINANCE Imbewu Entrepreneurship Finance would provides risk capital to new businesses and to early stage businesses owned and managed by black people meeting the following criteria:
More informationSpeed & scale to added sugars reduction: The ambition of the European soft drinks industry
> Speed & scale to added sugars reduction: The ambition of the European soft drinks industry Gloria Gabellini, Public Policy, Government Affairs & Communications Manager EU, PepsiCo Sigrid Ligné, Director
More informationPROACTIVE INVESTOR PRESENTATION
www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,
More informationThe MGH Journey. Shaping the Future of an Entire Region
The MGH Journey Shaping the Future of an Entire Region Navigating History, Building on Our Past Northwestern Hospital 1890 First General 1896 St. Luke s 1897 New St. Luke s opens 1915 Northern Michigan
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationCochlear Limited 2017 Annual General Meeting Chairman s Address
Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationDynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. Investora 2018 Dynamic Growth Gerhard Mahrle CFO COLTENE Holding AG September 2018 COLTENE AN INTERNATIONALLY
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationFully Employed MBA (MGMT FE)
Fully Employed MBA (MGMT FE) 1 Fully Employed MBA (MGMT FE) Courses MGMT FE 200. Responding to Dynamic Times: Thinking Strategically in Organizations. 6 Units. Focuses on the strategic and organizational
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More information